• Tuberculosis and Respiratory Diseases
• /
• v.80 no.2
• /
• pp.136-142
• /
• 2017

Assessing response to therapy allows for prospective end point evaluation in clinical trials and serves as a guide to clinicians for making decisions. Recent prospective and randomized trials suggest the development of imaging techniques and introduction of new anti-cancer drugs. However, the revision of methods, or proposal of new methods to evaluate chemotherapeutic response, is not enough. This paper discusses the characteristics of the Response Evaluation Criteria In Solid Tumor (RECIST) version 1.1 suggested in 2009 and used widely by experts. It also contains information about possible dilemmas arising from the application of response assessment by the latest version of the response evaluation method, or recently introduced chemotherapeutic agents. Further data reveals the problems and limitations caused by applying the existing RECIST criteria to anti-cancer immune therapy, and the application of a new technique, immune related response criteria, for the response assessment of immune therapy. Lastly, the paper includes a newly developing response evaluation method and suggests its developmental direction.

• Toxicological Research
• /
• v.33 no.1
• /
• pp.1-5
• /
• 2017

Nuclear factor E2-related factor 2 (Nrf2), a transcription factor, controls the expression of genes encoding cytoprotective proteins, including antioxidant enzymes that combat oxidative and electrophilic stress to maintain redox homeostasis. However, recent studies demonstrated that, in cancer, aberrant activation of Nrf2 by epigenetic alterations promotes high expression of cytoprotective proteins, which can decrease the efficacy of anticancer drugs used for chemotherapy. In this review, we summarize recent findings regarding the relationship between oxidative stress, Nrf2, epigenetic modification, and anticancer drug resistance, which should aid in development of new strategies to improve chemotherapeutic efficacy.

• Parasites, Hosts and Diseases
• /
• v.51 no.4
• /
• pp.393-400
• /
• 2013

Ocular toxoplasmosis is a disease caused by the infection with Toxoplasma gondii through congenital or acquired routes. Once the parasite reaches the retina, it proliferates within host cells followed by rupture of the host cells and invasion into neighboring cells to make primary lesions. Sometimes the restricted parasite by the host immunity in the first scar is activated to infect another lesion nearby the scar. Blurred vision is the main complaint of ocular toxoplasmic patients and can be diagnosed by detection of antibodies or parasite DNA. Ocular toxoplasmosis needs therapy with several combinations of drugs to eliminate the parasite and accompanying inflammation; if not treated it sometimes leads to loss of vision. We describe here clinical features and currently available chemotherapy of ocular toxoplasmosis.

• Journal of Preventive Medicine and Public Health
• /
• v.15 no.1
• /
• pp.139-143
• /
• 1982

A study was carried out in 81 retreatment patients with sputum positive pulmonary tuberculosis who had previously been treated with first-line drugs for more than one year at Health Center. The Following results were obtained; 1. Of the total 81 case of retreatment patients, male patients occupied 63(77.8%) and 18(22.2%) were female. Age group of $30{\sim}49$ years was 54.3% of total cases. 2. By extent of disease, moderate advanced cases were 53.1% and far advanced cases were 35.8%. 3. Of 81 patients admitted to the study. 65(80.3%) completed 1 year treatment 16(19.7%) patients discharged prematurely before 1 year. 4 patients terminated their treatment during $9{\sim}11$ months after registration. 4. Completment rate of chemotherapy was highest (90%) at age of under 30 years. 5. Intractable patients with persistant positive sputum test for A.F.B. even after 12 months of retreatment were occupied 9(13.8%) of total retreatment cases.

• BMB Reports
• /
• v.30 no.6
• /
• pp.421-425
• /
• 1997

The 4'-aminomethyl-4,5',8-trimethylpsoralen (AMT) has been used as intercalating DNA binding drugs in the photo-chemotherapy of skin diseases. The conformation and stability of DNA octamer duplex, $d(GGGTACCC)_2$, cross-linked with AMT has been studied by NMR spectroscopy. All the proton resonances of the psoralen cross-linked octamer were assigned and meting temperature studies were carried out based on the assignment of the proton resonances. The aromatic proton chemical shift data suggest that the conformation of the helix cross-linked with psoralen is destabilized more to furanside of the psoralen. possibly due to the protrusion of the aminomethyl side chain of the psoralen.

• Asian Pacific Journal of Cancer Prevention
• /
• v.17 no.2
• /
• pp.445-453
• /
• 2016

Epidermal growth factor receptors (EGFRs/HERs) and downstream signaling pathways have been implicated in the pathogenesis of several malignancies including breast cancer and its resistance to treatment with chemotherapeutic drugs. Consequently, several monoclonal antibodies as well as small molecule inhibitors targeting these pathways have emerged as therapeutic tools in the recent past. However, studies have shown that utilizing these molecules in combination with chemotherapy has yielded only limited success. This review describes the current understanding of EGFRs/HERs and associated signaling pathways in relation to development of breast cancer and responses to various cancer treatments in the hope of pointing to improved prevention, diagnosis and treatment. Also, we review the role of breast cancer stem cells (BCSCs) in disease and the potential to target these cells.

• Asian Pacific Journal of Cancer Prevention
• /
• v.13 no.12
• /
• pp.6533-6537
• /
• 2012

Cancers are significant contributors to the mortality and health care expenditures. Cancer can be reduced and monitored by new information technology. Radio frequency identification or RFID is a wireless identification technology. The use of this technology can be employed for identifying and tracking clinical staff, patients, supplies, medications and equipments. RFID can trace and manage chemotherapy drugs. There are different types of RFID. Implantable RFID allowing a chip to be embedded under the skin and that store the cancer patient's identifier. These are concerns about applications of RFID. Privacy, security and legal issues are key problems. This paper describes capabilities, benefits and confidentiality aspects in radio frequency identification systems and solutions for overcoming challenges.

• Advances in materials Research
• /
• v.6 no.2
• /
• pp.129-153
• /
• 2017

Platinum is a transition metal that is very resistant to corrosion. It is used as catalyst for converting methyl alcohol to formaldehyde, as catalytic converter in cars, for hydrocracking of heavy oils, in Fuel Cell devices etc. Moreover, Platinum compounds are important ingredient for cancer chemotherapy drugs. The nano forms of Platinum due to its unique physico-chemical properties that are not found in its bulk counterpart, has been found to be of great importance in electronics, optoelectronics, enzyme immobilization etc. The stability of Platinum nanoparticles has supported its use for the development of efficient and durable proton exchange membrane Fuel Cells. The present review concentrates on the use of Platinum conjugated with various metal or compounds, to fabricate nanocomposites, to enhance the efficiency of Platinum nanoparticles. The recent advances in the synthesis methods of different Platinum-based nanocomposites and their applications in Fuel Cell, sensors, bioimaging, light emitting diode, dye sensitized solar cell, hydrogen generation and in biosystems has also been discussed.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 2002.07a
• /
• pp.97-102
• /
• 2002

Life Science Research Center of SK Chemicals has developed a 3rd-generation anticancer platinum drug for the first time in the nation′s 100-year-old pharmaceutical industry. The Korea Food and Drug Administration (KFDA) approved the sale of "Sunpla" (code name SKI 2053R, general name : Heptaplatin) on July 14, 1999 for the treatment of advance, metastatic gastric cancer. Cisplatin, the 1 st-generation anticancer drug, which was developed by Bristol-Myers of the United States in 1976, is one of the most potent anticancer drugs and is a major component of combination chemotherapy for a variety of human cancers. However its clinical usefulness has frequently been limited not only by undesirable side effects such as severe renal toxicity, nausea, vomiting, ototoxicity, and neurotoxicity but also by the development of resistance. Carboplatin, the 2nd-generation anticancer platinum drug, which was also developed by Bristol-Myers in 1986, has modified the problems of the renal and gastrointestinal toxicities of cisplatin. Carboplatin, however, has no enhanced therapeutic efficacy over cisplatin and does not possess the property to overcome cross-resistance to cisplatin.

• Journal of Pharmaceutical Investigation
• /
• v.37 no.5
• /
• pp.287-290
• /
• 2007

Intrinsic or acquired resistance to chemotherapeutic drugs is one of the major obstacles to effective cancer treatment. Hypoxia is widespread in solid tumors as a consequence of decreased blood flow in the tumor-derived neovasculature. The recent finding of a link between hypoxia and chemoresistance prompted us to investigate whether hypoxia induces doxorubicin resistance in human MCF-7 breast cancer cells. Low oxygen concentration decreased the doxorubicin sensitivity in MCF-7 cells. The expression of p-glycoprotein, a major MDR-related transporter, and those of apoptosis-related proteins (anti-apoptotic Bcl-2, Bcl-XL and pro-apoptotic Bax) were not altered by hypoxia in MCF-7 cells. Intracellular uptake of doxorubicin was significantly decreased under hypoxic conditions. Decreased cellular uptake of doxorubicin under hypoxia may contribute to causing doxorubicin resistance in these cells. The use of agents that can modulate the doxorubicin uptake for adjuvant therapy may contribute to improving the therapeutic efficacy of doxorubicin in breast cancer patients.